ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

Phase 1 Terminated 23 enrolled MEI Pharma, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1b open-label, multiple dose/schedule sequential study to determine the safety and efficacy of the oxidative phosphorylation (OxPhos) pathway inhibitor ME-344 in combination with bevacizumab in subjects with recurrent mCRC.

Timeline

Start: 2023-08-07
Primary completion: 2024-07-09
Completion: 2024-07-23

Outcome

Outcome not reported

Stopped (Business): “Company decision to wind down operations, close all clinical programs and evaluate strategic options”

Publications

Boland PM, Lenz HJ, Ciombor KK, Florou V, Pishvaian MJ, Cusnir M, Cohen D, Guo JY, Tang M, Rajagopalan P, Wiley SE, Ghalie RG, Hochster HS. A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer. Invest New Drugs. 2025 Feb;43(1):60-68. doi: 10.1007/s10637-024-01489-1. Epub 2024 Dec 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	—	Intravenous
Subject	ME-344	Small molecule	—	Intravenous